Goldman Sachs analyst Eric Sheridan raised the firm’s price target on GoodRx to $6.50 from $6 and keeps a Neutral rating on the shares. Ahead of the Q4 earnings season, the analyst updated operating estimates and valuations across the firm’s small and mid-cap internet group. Looking to 2024, Goldman sees the potential for returns to be driven by stock-picking based on idiosyncratic fundamentals, as opposed to the bifurcation seen in 2023 where mega-cap names as a group outperformed the rest of the space.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on GDRX:
- GoodRx to eliminate role currently held by Chief Operating Officer Raj Beri
- GoodRx price target raised to $7 from $5 at RBC Capital
- GoodRx price target raised to $7.50 from $5.50 at Truist
- GoodRx Stock (NASDAQ:GDRX) Gained on Upbeat Q4 Preliminary Results
- GoodRx pre-announcement ‘directionally positive,’ says Wells Fargo